Key Drivers
- Net cash
- Margin pressure
- Q1 cash burn
AIAI Summary
CSTL looks like a cash-rich diagnostics story with real clinical traction, but the investment case now hinges on whether revenue can scale fast enough to turn heavy operating costs and volatile cash flow into durable earnings power; until that operating leverage shows up, it remains more of a turnaround watchlist name than a clean buy.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net cash
- •Margin pressure
- •Q1 cash burn
CSTL has a strong cash-rich balance sheet and high gross margins, but persistent operating losses and worsening Q1 cash burn limit near-term investment appeal.
Price Behavior
Key Price Behavior Insights:
- •Downtrend persists
- •Support holding
- •Fragile rebound
CSTL has been in a clear downtrend over the last month, with an abrupt May break and a rebound from $18.15-$19.13 suggesting tentative basing, but it still needs to reclaim $20.54 and then $24.50 to materially improve the trend.
Abrupt break started on 2026-05-07 after a close near $24.75, signaling a sharp trend reset
Sentiment & News
Key News Insights:
- •Revenue beat
- •Guidance raised
- •Clinical validation
Castle Biosciences delivered a revenue beat, raised 2026 guidance, and added clinical/award momentum, reinforcing a constructive outlook for CSTL.
The latest updates should support investor confidence by highlighting both commercial execution and continued product credibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings